Medicare Part D drugs starting with E
119 drugs start with E; 52 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Eliquis in 2024: $20.8 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with E?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| E.E.S. (erythromycin ethylsuccinate) | 18.9% | Tier 4 | $35 thousand |
| Ebglyss (lebrikizumab-lbkz) | 18.7% | Tier 5 | $3 million |
| Econazole nitrate | 70.5% | Tier 2 | $5 million |
| Edarbi (azilsartan medoxomil) | 51.6% | Tier 4 | $37 million |
| Edarbyclor (azilsartan medoxomil / chlorthalidone) | 52.1% | Tier 4 | $26 million |
| Edluar (zolpidem tartrate) | 0.4% | Tier 4 | $739 thousand |
| Edurant (rilpivirine) | 100% | Tier 5 | $24 million |
| Efavirenz | 100% | Tier 4 | $4 million |
| Efavirenz / emtricitabine / tenofovir disoproxil fumarate | 100% | Tier 4 | no 2024 match |
| Efavirenz / lamivudine / tenofovir disoproxil fumarate | 100% | Tier 5 | $720 thousand |
| Effexor (venlafaxine) | under 0.1% | Tier 1 | $24 million |
| Egrifta (tesamorelin) | 4.4% | Tier 5 | $37 million |
| Ekterly (sebetralstat) | 2.4% | Tier 5 | no 2024 match |
| Elestrin (estradiol) | 0.4% | Tier 4 | $280 thousand |
| Eletriptan | 37.2% | Tier 2 | $6 million |
| Eligard (leuprolide acetate) | 95.3% | Tier 4 | $12 million |
| Eliquis (apixaban) | 100% | Tier 3 | $20.8 billion |
| Elmiron (pentosan polysulfate) | 48.2% | Tier 4 | $52 million |
| Eltrombopag | 56.6% | Tier 5 | no 2024 match |
| EluRyng (ethinyl estradiol / etonogestrel) | 94% | Tier 3 | $349 thousand |
| Elyxyb (celecoxib) | 0.2% | Tier 4 | $2 million |
| Emend (aprepitant) | 16.1% | Tier 4 | $130 thousand |
| Emgality (galcanezumab-gnlm) | 77.5% | Tier 3 | $305 million |
| Empaveli (pegcetacoplan) | 2.8% | Tier 5 | $29 million |
| Emrosi (minocycline) | 2.3% | Tier 5 | no 2024 match |
| Emsam (selegiline) | 100% | Tier 5 | $13 million |
| Emtricitabine | 100% | Tier 4 | $2 million |
| Emtricitabine / rilpivirine / tenofovir disoproxil fumarate | 100% | Tier 5 | no 2024 match |
| Emtricitabine / tenofovir disoproxil fumarate | 100% | Tier 4 | no 2024 match |
| Emtriva (emtricitabine) | 100% | Tier 4 | $228 thousand |
| Emverm (mebendazole) | 40.5% | Tier 5 | $6 million |
| Enalapril maleate | 100% | Tier 1 | $35 million |
| Enalapril maleate / hydrochlorothiazide | 97.7% | Tier 1 | $1 million |
| Enbrel (etanercept) | 100% | Tier 5 | $3.0 billion |
| Enbumyst (bumetanide) | 1.5% | Tier 5 | no 2024 match |
| Endari (glutamine) | 3.7% | Tier 5 | $5 million |
| Engerix-B (hepatitis B vaccine) | 100% | Tier 1 | no 2024 match |
| Enilloring (ethinyl estradiol / etonogestrel) | 81.9% | Tier 3 | $194 thousand |
| Enoby (denosumab-qbde) | 0.5% | Tier 4 | no 2024 match |
| Enoxaparin sodium | 100% | Tier 4 | $80 million |
Show the other 79 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Ensacove (ensartinib) | 100% | Tier 5 | no 2024 match |
| Enskyce (desogestrel / ethinyl estradiol) | 94.5% | Tier 2 | $81 thousand |
| Enspryng (satralizumab-mwge) | 2.4% | Tier 5 | $45 million |
| Enstilar (betamethasone dipropionate / calcipotriene) | 15.6% | Tier 5 | $7 million |
| Entacapone | 100% | Tier 4 | $20 million |
| Entecavir | 100% | Tier 4 | $27 million |
| Entresto (sacubitril / valsartan) | 100% | Tier 3 | $4.0 billion |
| Entyvio (vedolizumab) | 9.1% | Tier 5 | $157 million |
| Enulose (lactulose) | 99.9% | Tier 2 | $6 million |
| Envarsus (tacrolimus) | 69.5% | Tier 4 | $17 million |
| Eohilia (budesonide) | 2% | Tier 5 | $2 million |
| Epclusa (sofosbuvir / velpatasvir) | 60.1% | Tier 5 | $758 million |
| Epidiolex (cannabidiol) | 100% | Tier 5 | $207 million |
| Epinastine hydrochloride | 48.5% | Tier 3 | $2 million |
| Epinephrine | 100% | Tier 3 | $119 million |
| Epipen (epinephrine) | 0.2% | Tier 4 | $167 thousand |
| Epivir (lamivudine) | under 0.1% | Tier 1 | $65 thousand |
| Eplerenone | 80.1% | Tier 2 | $27 million |
| Epogen (epoetin alfa) | 1.4% | Tier 4 | $8 million |
| Eprontia (topiramate) | 61.2% | Tier 4 | $896 thousand |
| Equetro (carbamazepine) | 1.3% | Tier 4 | $1 million |
| Eraxis (anidulafungin) | 4.2% | Tier 4 | $483 thousand |
| Ergomar (ergotamine tartrate) | 4.3% | Tier 4 | $207 thousand |
| Erivedge (vismodegib) | 100% | Tier 5 | $117 million |
| Erleada (apalutamide) | 100% | Tier 5 | $1.4 billion |
| Erlotinib | 100% | Tier 5 | $7 million |
| Ermeza (levothyroxine sodium) | under 0.1% | Tier 2 | $17 thousand |
| Errin (norethindrone) | 96% | Tier 2 | $113 thousand |
| Ertaczo (sertaconazole) | 12.3% | Tier 4 | $5 million |
| Ertapenem | 100% | Tier 4 | $73 million |
| Ery (erythromycin) | 71% | Tier 3 | $95 thousand |
| Erythrocin (erythromycin lactobionate) | 45.5% | Tier 4 | no 2024 match |
| Erythromycin | 100% | Tier 2 | $30 million |
| Erythromycin ethylsuccinate | 28.4% | Tier 4 | $4 million |
| Erzofri (paliperidone palmitate) | 34.9% | Tier 4 | no 2024 match |
| Esbriet (pirfenidone) | under 0.1% | Tier 1 | $42 million |
| Escitalopram | 100% | Tier 1 | $141 million |
| Eslicarbazepine acetate | 100% | Tier 5 | no 2024 match |
| Esomeprazole | 94.2% | Tier 2 | $124 million |
| Esomeprazole / naproxen | 0.5% | Tier 4 | $16 million |
| Estarylla (ethinyl estradiol / norgestimate) | 96% | Tier 2 | $234 thousand |
| Estazolam | 3.7% | Tier 2 | $4 million |
| Estrace (estradiol) | 2.3% | Tier 1 | $2 million |
| Estradiol | 100% | Tier 1 | $218 million |
| Estradiol / norethindrone acetate | 74.8% | Tier 4 | $5 million |
| Estradiol valerate | 88.4% | Tier 4 | $2 million |
| Estring (estradiol) | 62.6% | Tier 4 | $49 million |
| Estrogens, conjugated | 49.6% | Tier 2 | no 2024 match |
| Eszopiclone | 54.4% | Tier 1 | $19 million |
| Ethacrynic acid | 21.6% | Tier 4 | $6 million |
| Ethambutol hydrochloride | 100% | Tier 2 | $4 million |
| Ethinyl estradiol | 75.7% | Tier 2 | no 2024 match |
| Ethinyl estradiol / etonogestrel | 97.2% | Tier 3 | $665 thousand |
| Ethinyl estradiol / levonorgestrel | 97.2% | Tier 2 | no 2024 match |
| Ethinyl estradiol / norelgestromin | 91.7% | Tier 3 | no 2024 match |
| Ethinyl estradiol / norethindrone acetate | 97.2% | Tier 2 | no 2024 match |
| Ethinyl estradiol / norgestimate | 96.8% | Tier 2 | no 2024 match |
| Ethosuximide | 100% | Tier 3 | $1 million |
| Etodolac | 95.7% | Tier 2 | $11 million |
| Etravirine | 100% | Tier 5 | $23 million |
| Eucrisa (crisaborole) | 58.6% | Tier 4 | $9 million |
| Eulexin (flutamide) | 100% | Tier 5 | $161 thousand |
| Evamist (estradiol) | 0.9% | Tier 4 | $376 thousand |
| Evenity (romosozumab-aqqg) | 2.2% | Tier 5 | $94 million |
| Everolimus | 100% | Tier 4 | $143 million |
| Evista (raloxifene hydrochloride) | under 0.1% | Tier 1 | $925 thousand |
| Evotaz (atazanavir / cobicistat) | 100% | Tier 5 | $10 million |
| Evoxac (cevimeline hydrochloride) | 0.1% | Tier 4 | $1 million |
| Evrysdi (risdiplam) | 9% | Tier 5 | $155 million |
| Exelon (rivastigmine) | under 0.1% | Tier 1 | $10 million |
| Exemestane | 100% | Tier 4 | $32 million |
| Exenatide | 2.2% | Tier 3 | no 2024 match |
| Exforge (amlodipine / valsartan) | under 0.1% | Tier 1 | $2 million |
| Exforge HCT (amlodipine / hydrochlorothiazide / valsartan) | under 0.1% | Tier 1 | $650 thousand |
| Exjade (deferasirox) | under 0.1% | Tier 1 | $3 million |
| Exxua (gepirone) | 100% | Tier 5 | no 2024 match |
| Eysuvis (loteprednol etabonate) | 49.1% | Tier 4 | $13 million |
| Ezetimibe | 100% | Tier 2 | $209 million |
| Ezetimibe / simvastatin | 94.3% | Tier 1 | $24 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans